UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 9, 2007
Pain Therapeutics
(Exact name of registrant as specified in its charter)
|
Delaware |
000-29959 |
91-1911336 |
||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
416 Browning Way, South San Francisco, CA |
94080 |
|||
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (650) 624-8200
________________________________________________________________________________
(Former name or former address, if changed since last report)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | ||
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Item 2.02. Results of Operations and Financial Condition.
On August 9, 2007 Pain Therapeutics, Inc. (the "Company") issued a press release announcing the Company's financial results for the three and six months ended June 30, 2007. A copy of the press release has been furnished as an exhibit to this report and is incorporated by reference herein.
The information in this Current Report on Form 8-K and in Exhibit 99.1 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference into any registration statement or other document filed or furnished pursuant to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
The following exhibit is furnished as part of this Current Report on Form 8-K.
Exhibit
Number Description
99.1 Press Release of Pain Therapeutics, Inc. dated August 9, 2007.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Pain Therapeutics
(Registrant) |
||
|
August 9, 2007
(Date) |
/s/ PETER S. RODDY
Peter S. Roddy Chief Financial Officer |
| Exhibit Index | ||
| 99.1 | Press release dated August 9, 2007 | |
EXHIBIT 99.1
Pain Therapeutics Announces Second Quarter 2007 Financial Results
SOUTH SAN FRANCISCO, Calif. , Aug. 9, 2007 (PRIME NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the three and six months ended June 30, 2007. Net income for the quarter ended June 30, 2007 was $3.4 million, or $0.07 per diluted share, compared to $1.4 million, or $0.03 per share, in the second quarter of 2006. Net income for the six months ended June 30, 2007 was $16.0 million, or $0.35 per diluted share, compared to $2.2 million, or $0.05 per share, for the same period in 2006.
Cash, cash equivalents and marketable securities were $206.3 million at June 30, 2007. Pain Therapeutics continues to expect its 2007 net cash requirements to be approximately $10.0 million, plus any amounts related to a previously announced stock buyback plan of up to $20.0 million of its common stock. As of June 30, 2007 we had purchased $3.8 million of our common stock on the open market.
Financial Highlights
-- We have a collaboration with King Pharmaceuticals, Inc. ("King")
to develop Remoxy(tm) and other abuse-deterrent opioid
painkillers. Collaboration revenues were $7.5 million and $23.0
million in the three and six months ended June 30, 2007,
respectively and $7.2 million and $16.0 million in the three and
six months ended June 30, 2006, respectively. Collaboration revenue
in the six months ended June 30, 2007 includes reimbursement from
King of certain of our development expenses during that period as
well as $5.9 million of expenses we incurred in 2006 related to the
collaboration that were not recognized in 2006. King completed
its review and reimbursed us for $5.7 million of these expenses
during the three months ended March 31, 2007 and for $0.2 million
of these expenses during the three months ended June 30, 2007.
-- On March 29, 2007, we announced a stock buyback plan of up to
$20.0 million of our common stock. As of June 30, 2007 we had
purchased $3.8 million of our common stock on the open market.
The total number of shares to be purchased and the timing of
purchases will be based on several factors, including the price
of the common stock, general market conditions, corporate and
regulatory requirements and alternate investment opportunities.
We intend to hold repurchased shares in treasury. This stock
buyback program expires March 2008 and may be modified or
discontinued at any time.
-- King gave us an upfront cash payment of $150.0 million in December
2005. For accounting purposes, we plan to recognize a portion of
this cash payment as "program fee revenue" each quarter through
July 2011. We recognized program fee revenue of $6.6 million this
quarter.
-- Research and development expenses for the second quarter of 2007
increased to $11.0 million from $10.2 million for the second
quarter of 2006. Research and development expenses for the six
months ended June 30, 2007 decreased to $20.9 million from $23.0
million for the same period in 2006. These fluctuations were
primarily due to the timing of development activities for our
abuse-deterrent drug candidates. Research and development
expenses included non-cash stock related compensation costs of
$0.8 million in the three months ended June 30, 2007 and 2006 and
$1.5 million and $1.8 million in the six months ended June 30,
2007 and 2006, respectively.
-- General and administrative expenses increased to $2.1 million from
$2.0 million in the three months ended June 30, 2007 and 2006,
respectively, and decreased to $3.9 million from $4.0 million in
the six months ended June 30, 2007 and 2006, respectively. General
and administrative expenses included non-cash stock related
compensation costs of $0.6 million in the three months ended June
30, 2007 and 2006 and $1.1 million and $1.4 million in the six
months ended June 30, 2007 and 2006, respectively.
-- We have not provided for income taxes for the second quarter of
2007 because we do not expect to have taxable income for the full
year 2007. Our income before income taxes in 2007 includes
program fee revenue. For tax purposes, we recognized all of the
related program fee revenue in 2006, which is the primary reason
for our expectations for no taxable income for 2007.
About Pain Therapeutics, Inc.
Pain Therapeutics is a biopharmaceutical company that develops novel drugs. We have four investigational drug candidates in clinical programs, including Remoxy, Oxytrex(tm), PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. We are also working on a new treatment for patients with hemophilia. The FDA has not yet evaluated the merits, safety or efficacy of our drug candidates. For more information, please visit www.paintrials.com.
Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates, and the Company's expected cash requirements in 2007. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development and testing of the Company's drug candidates, unexpected adv erse side effects or inadequate therapeutic efficacy of the Company's drug candidates (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the uncertainty of patent protection for the Company's intellectual property or trade secrets and unanticipated research and development and other costs. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.
PAIN THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended June 30, Six Months Ended June 30,
-------------------------- ------------------------
2007 2006 2007 2006
---- ---- ---- -----
Revenue
Program fee
revenue $ 6,550 $ 6,550 $ 13,100 $ 13,100
Collaboration
revenue 7,515 7,196 23,018 15,972
--------- --------- --------- ---------
Total revenue 14,065 13,746 36,118 29,072
Operating expenses
Research and
development 11,044 10,188 20,903 23,042
General and
administrative 2,102 2,049 3,940 4,019
--------- --------- --------- ---------
Total operating
expenses 13,146 12,237 24,843 27,061
--------- --------- --------- ---------
Operating income 919 1,509 11,275 2,011
Interest and other
income 2,446 2,468 4,726 4,556
--------- --------- --------- ---------
Income before
provision for
income taxes 3,365 3,977 16,001 6,567
Provision for
income taxes -- 2,610 -- 4,323
--------- --------- --------- ---------
Net income $ 3,365 $ 1,367 $ 16,001 $ 2,244
========= ========= ========= =========
Earnings per share
Basic $ 0.08 $ 0.03 $ 0.36 $ 0.05
========= ========= ========= =========
Diluted $ 0.07 $ 0.03 $ 0.35 $ 0.05
========= ========= ========= =========
Weighted-average
shares used in
computing
earnings per share
Basic 44,025 44,138 44,183 44,067
========= ========= ========= =========
Diluted 45,180 45,258 45,303 45,381
========= ========= ========= =========
PAIN THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands)
June 30, December 31,
2007 2006 (1)
-------------- --------------
(Unaudited)
Assets
Current assets
Cash, cash equivalents and
marketable securities $ 206,327 $ 204,400
Other current assets 332 2,714
---------- ----------
Total current assets 206,659 207,114
Non-current assets
Property and equipment, net 1,206 1,267
Other assets 768 75
---------- ----------
Total assets $ 208,633 $ 208,456
========== ==========
Liabilities and stockholders' equity
Current liabilities
Accounts payable $ 2,220 $ 985
Accrued development expense 4,014 5,777
Deferred program fee revenue -
current portion 26,200 26,200
Income taxes payable -- 2,779
Other accrued liabilities 1,141 913
---------- ----------
Total current liabilities 33,575 36,654
Non-current liabilities
Deferred program fee revenue -
non-current portion 80,787 93,887
Other liabilities 760 --
---------- ----------
Total liabilities 115,122 130,541
---------- ----------
Stockholders' equity
Common stock 44 44
Additional paid-in-capital 216,077 214,749
Accumulated other comprehensive loss (177) (372)
Accumulated deficit (122,433) (136,506)
---------- ----------
Total stockholders' equity 93,511 77,915
---------- ----------
Total liabilities and stockholders'
equity $ 208,633 $ 208,456
========== ==========
(1) Derived from audited financial statements.
CONTACT: Pain Therapeutics, Inc.
Christi Waarich, Senior Manager of Investor Relations
650-825-3324
cwaarich@paintrials.com
Burns McClellan
Media
Carney Noensie
212-213-0006